{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:24:56Z","timestamp":1789575896204,"version":"build-2803163510"},"reference-count":218,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.critrevonc.2024.104483","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T11:49:56Z","timestamp":1723895396000},"page":"104483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-0152","authenticated-orcid":false,"given":"Carolina","family":"Reduzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nicolo\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ortega-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"de Miguel-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Dipasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick F.","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pashtoon M.","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Jantus-Lewintre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104483_bib2","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104483_bib3","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2016.02.024","article-title":"Tumor heterogeneity and circulating tumor cells","volume":"374","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt.2892","article-title":"Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer","volume":"32","author":"Lohr","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104483_bib6","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1158\/1078-0432.CCR-18-0862","article-title":"Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis","volume":"24","author":"Lambros","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104483_bib7","article-title":"Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells","volume":"9","author":"Dago","year":"2014"},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104483_bib8","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-17-1173","article-title":"Detection of activating estrogen receptor gene ( ESR1) mutations in single circulating tumor cells","volume":"23","author":"Paolillo","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104483_bib9","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1158\/1078-0432.CCR-19-1176","article-title":"Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK -rearranged non\u2013small-cell lung cancer","volume":"25","author":"Pailler","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nm.4239","article-title":"Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer","volume":"23","author":"Carter","year":"2017","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"6119","key":"10.1016\/j.critrevonc.2024.104483_bib12","first-page":"580","article-title":"Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition","volume":"339","author":"Yu","year":"2013","journal-title":"Science (1979)"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111750","article-title":"Post-surgery circulating tumor cells and AXL overexpression as new poor prognostic biomarkers in resected lung adenocarcinoma","volume":"11","author":"De Miguel-P\u00e9rez","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1663-8","article-title":"Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study","volume":"16","author":"Horimoto","year":"2018","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/cancers11040483","article-title":"Heterogeneity in circulating tumor cells: the relevance of the stem-cell subset","volume":"11","author":"Agnoletto","year":"2019","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104483_bib16","doi-asserted-by":"crossref","first-page":"12337","DOI":"10.3390\/ijms241512337","article-title":"Deciphering the biology of circulating tumor cells through single-cell RNA sequencing: implications for precision medicine in cancer","volume":"24","author":"Orrapin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib18","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10555-023-10124-z","article-title":"How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy","volume":"42","author":"Nasr","year":"2023","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","article-title":"Better together: circulating tumor cell clustering in metastatic cancer","volume":"7","author":"Schuster","year":"2021","journal-title":"Trends Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib20","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.7150\/thno.64252","article-title":"Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior","volume":"12","author":"Rodriguez-Martinez","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94735-y","article-title":"Interactions of platelets with circulating tumor cells contribute to cancer metastasis","volume":"11","author":"Anvari","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2024.104483_bib22","first-page":"57","article-title":"Models to study CTCs and CTC culture methods","author":"Fern\u00e1ndez-Santiago","year":"2023","journal-title":"In"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"180","key":"10.1016\/j.critrevonc.2024.104483_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005109","article-title":"The identification and characterization of breast cancer CTCs competent for brain metastasis","volume":"5","author":"Zhang","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104483_bib26","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.18632\/oncotarget.2592","article-title":"Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ijc.11479","article-title":"Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis","volume":"107","author":"Gaforio","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104483_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2018.12.004","article-title":"The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper","volume":"134","author":"Cristofanilli","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib31","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","article-title":"Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer","volume":"23","author":"Cristofanilli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1634\/theoncologist.2012-0479","article-title":"Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer","volume":"18","author":"Mart\u00edn","year":"2013","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib34","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-14-1913","article-title":"Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor\u2013positive breast cancer","volume":"21","author":"Paoletti","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.critrevonc.2024.104483_bib35","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"Smerage","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnci\/djaa113","article-title":"Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy","volume":"113","author":"Magbanua","year":"2021","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"6_Supplement","key":"10.1016\/j.critrevonc.2024.104483_bib37","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1158\/1538-7445.AM2024-7500","article-title":"Abstract 7500: distribution and prognostic significance of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in patients (pts) with lobular metastatic breast cancer (MBC)","volume":"84","author":"Nicolo","year":"2024","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib38","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/cells9071718","article-title":"The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast\u2014long-term prognostic significance","volume":"9","author":"Narbe","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.neo.2016.08.007","article-title":"Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor","volume":"18","author":"Beije","year":"2016","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-012-2045-1","article-title":"Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study","volume":"134","author":"Pestrin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10549-020-05662-x","article-title":"Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors","volume":"181","author":"Wang","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100299","article-title":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program","volume":"6","author":"M\u00fcller","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/1878-0261.12017","article-title":"Epithelial-mesenchymal transition in tumor metastasis","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13058-016-0687-3","article-title":"In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis","volume":"18","author":"Bulfoni","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","article-title":"The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer","volume":"39","author":"Guan","year":"2019","journal-title":"Cancer Commun."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104483_bib46","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/cancers14215238","article-title":"A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the parsortix\u00ae PC1 system","volume":"14","author":"Cohen","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib47","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00384-018-03223-9","article-title":"Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients","volume":"34","author":"Wang","year":"2019","journal-title":"Int. J. Colorectal Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/jpm10040235","article-title":"Evaluation of the role of circulating tumor cells and microsatellite instability status in predicting outcome of advanced CRC patients","volume":"10","author":"Messaritakis","year":"2020","journal-title":"J. Pers. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib49","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/diagnostics11030502","article-title":"Baseline and kinetic circulating tumor cell counts are prognostic factors in a prospective study of metastatic colorectal cancer","volume":"11","author":"Silva","year":"2021","journal-title":"Diagnostics"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib50","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib51","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/PO.20.00200","article-title":"Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer","author":"Armstrong","year":"2020","journal-title":"JCO Precis Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104483_bib52","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1158\/0008-5472.CAN-20-1216","article-title":"Morphology-predicted large-scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer","volume":"80","author":"Schonhoft","year":"2020","journal-title":"Cancer Res."},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104483_bib53","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1200\/JCO.2017.72.4138","article-title":"Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-na\u00efve, metastatic, castration-resistant prostate cancer","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib54","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2010.28.7045","article-title":"Evaluation and prognostic significance of circulating tumor cells in patients with non\u2013small-cell lung cancer","volume":"29","author":"Krebs","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib55","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdx156","article-title":"A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups","volume":"28","author":"Lindsay","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104483_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017750121","article-title":"Evaluation of PD-L1\/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer","volume":"10","author":"Kallergi","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/ijms18051035","article-title":"Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy","volume":"18","author":"Coco","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"47","key":"10.1016\/j.critrevonc.2024.104483_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005115","article-title":"Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib60","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-16-3072","article-title":"Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK -rearranged non\u2013small cell lung cancer patients","volume":"77","author":"Pailler","year":"2017","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib61","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1078-0432.CCR-15-1031","article-title":"Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses","volume":"22","author":"Sundaresan","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104483_bib62","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1039\/D0TB00589D","article-title":"A circulating tumor cell-based digital assay for the detection of EGFR T790M mutation in advanced non-small cell lung cancer","volume":"8","author":"Wang","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib63","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.resinv.2021.03.010","article-title":"Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer","volume":"59","author":"Isobe","year":"2021","journal-title":"Respir. Invest."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib64","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41598-018-19245-w","article-title":"Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer","volume":"8","author":"Dhar","year":"2018","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104483_bib65","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1002\/cam4.4236","article-title":"Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: a systematic review and meta-analysis","volume":"10","author":"Ouyang","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"Ili\u00e9","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/srep31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab","volume":"6","author":"Nicolazzo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2024.104483_bib68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2018.04.001","article-title":"PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab","volume":"120","author":"Guibert","year":"2018","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib69","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1002\/cam4.1832","article-title":"The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer","volume":"7","author":"Kulasinghe","year":"2018","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib70","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/clinchem\/hvab131","article-title":"Programmed cell death ligand 1-expressing circulating tumor cells: a new prognostic biomarker in non-small cell lung cancer","volume":"67","author":"Sinoquet","year":"2021","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib71","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s40425-019-0649-2","article-title":"Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors","volume":"7","author":"Tamminga","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib72","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-019-2035-8","article-title":"Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer","volume":"17","author":"Shishido","year":"2019","journal-title":"J. Transl. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib73","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.21037\/tlcr-21-100","article-title":"Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib74","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/1878-0261.13317","article-title":"Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab","volume":"17","author":"Spiliotaki","year":"2023","journal-title":"Mol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib75","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/jcm8071011","article-title":"Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with Nivolumab","volume":"8","author":"Alama","year":"2019","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib76","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","article-title":"Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer","volume":"30","author":"Hou","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib77","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1093\/annonc\/mds138","article-title":"Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor","volume":"23","author":"Hiltermann","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104483_bib78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lungcan.2017.08.008","article-title":"Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy","volume":"112","author":"Aggarwal","year":"2017","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib79","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","article-title":"Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer","volume":"30","author":"Hou","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104483_bib80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lungcan.2019.06.025","article-title":"Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment","volume":"135","author":"Messaritakis","year":"2019","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib81","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/onco.13842","article-title":"Prognostic role of circulating tumor cells in metastatic renal cell carcinoma: a large, multicenter, prospective trial","volume":"26","author":"Basso","year":"2021","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib82","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/1878-0261.12931","article-title":"Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma","volume":"15","author":"Bade","year":"2021","journal-title":"Mol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib83","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1464-410X.2010.09562.x","article-title":"Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer","volume":"107","author":"Rink","year":"2011","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib84","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.urology.2011.05.045","article-title":"Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma","volume":"78","author":"Flaig","year":"2011","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/annonc\/mdn627","article-title":"Detection of circulating tumor cells in patients with urothelial cancer","volume":"20","author":"Gallagher","year":"2009","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib86","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cam4.3616","article-title":"Circulating CEA-positive and EpCAM-negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer","volume":"10","author":"Miki","year":"2021","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib87","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1111\/cas.14654","article-title":"Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor","volume":"111","author":"Kuroda","year":"2020","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib88","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cam4.3616","article-title":"Circulating CEA-positive and EpCAM-negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer","volume":"10","author":"Miki","year":"2021","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib89","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-021-04251-z","article-title":"Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer","volume":"87","author":"Matsushita","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib90","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1111\/cas.14654","article-title":"Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor","volume":"111","author":"Kuroda","year":"2020","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-021-04251-z","article-title":"Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer","volume":"87","author":"Matsushita","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib92","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdt176","article-title":"Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial","volume":"24","author":"Bidard","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib93","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3748\/wjg.v25.i1.138","article-title":"Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice","volume":"25","author":"Zhao","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104483_bib94","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2019.03.009","article-title":"Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer","volume":"452","author":"Wei","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2024.104483_bib95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2019.03.009","article-title":"Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer","volume":"452","author":"Wei","year":"2019","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib96","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib98","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib99","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104483_bib100","doi-asserted-by":"crossref","first-page":"24303","DOI":"10.18632\/oncotarget.13286","article-title":"ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib101","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib102","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104483_bib103","doi-asserted-by":"crossref","first-page":"24303","DOI":"10.18632\/oncotarget.13286","article-title":"ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000445999","article-title":"Enumeration and molecular characterisation of circulating tumour cells in endometrial cancer","volume":"91","author":"Lemech","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2024.104483_bib105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","article-title":"Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer","volume":"43","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib106","first-page":"1525","article-title":"Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma","volume":"43","author":"Liu","year":"2020","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib107","first-page":"1525","article-title":"Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma","volume":"43","author":"Liu","year":"2020","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000646","article-title":"Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma","volume":"5","author":"Economopoulou","year":"2020","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib109","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1373\/clinchem.2019.305904","article-title":"Circulating tumor cells as a prognostic factor in recurrent or metastatic head and neck squamous cell carcinoma: the CIRCUTEC prospective study","volume":"65","author":"Garrel","year":"2019","journal-title":"Clin. Chem."},{"issue":"247","key":"10.1016\/j.critrevonc.2024.104483_bib110","doi-asserted-by":"crossref","first-page":"247ra101","DOI":"10.1126\/scitranslmed.3009095","article-title":"Hematogenous dissemination of glioblastoma multiforme","volume":"6","author":"M\u00fcller","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"44","key":"10.1016\/j.critrevonc.2024.104483_bib111","doi-asserted-by":"crossref","first-page":"71330","DOI":"10.18632\/oncotarget.11114","article-title":"Circulating tumor cell is a common property of brain glioma and promotes the monitoring system","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib112","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.1990.8.4.736","article-title":"Detection of neuroblastoma cells in blood","volume":"8","author":"Moss","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib113","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1078-0432.CCR-19-0656","article-title":"Detection of circulating and disseminated neuroblastoma cells using the imageStream flow cytometer for use as predictive and pharmacodynamic biomarkers","volume":"26","author":"Merugu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"44","key":"10.1016\/j.critrevonc.2024.104483_bib114","doi-asserted-by":"crossref","first-page":"71330","DOI":"10.18632\/oncotarget.11114","article-title":"Circulating tumor cell is a common property of brain glioma and promotes the monitoring system","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1078-0432.CCR-19-0656","article-title":"Detection of circulating and disseminated neuroblastoma cells using the imageStream flow cytometer for use as predictive and pharmacodynamic biomarkers","volume":"26","author":"Merugu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1078-0432.CCR-15-1008","article-title":"Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms","volume":"22","author":"Khan","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib117","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41416-020-01227-3","article-title":"Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial","volume":"124","author":"Cabel","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","article-title":"Efficacy of circulating tumor cell count\u2013driven vs clinician-driven first-line therapy choice in hormone receptor\u2013positive, ERBB2-negative metastatic breast cancer","volume":"7","author":"Bidard","year":"2021","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib119","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.23.00456","article-title":"Overall survival with circulating tumor cell count\u2013driven choice of therapy in advanced breast cancer: a randomized trial","volume":"42","author":"Bidard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104483_bib120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01940","article-title":"PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor\u2013positive\/human epidermal growth factor receptor\u2013negative metastatic breast","author":"Mayer","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104483_bib121","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2023.41.16_suppl.1059","article-title":"Circulating tumor cells (CTCs) dynamics after CDK4\/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): a biomarker analysis of the PACE randomized phase II study","volume":"41","author":"Gerratana","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib122","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-010-1163-x","article-title":"HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial","volume":"124","author":"Fehm","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib123","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-009-0461-7","article-title":"Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients","volume":"118","author":"Pestrin","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"25","key":"10.1016\/j.critrevonc.2024.104483_bib124","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1073\/pnas.0402993101","article-title":"HER-2 gene amplification can be acquired as breast cancer progresses","volume":"101","author":"Meng","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-012-2045-1","article-title":"Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study","volume":"134","author":"Pestrin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-019-1215-z","article-title":"Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial","volume":"21","author":"Jacot","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104483_bib127","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-023-07231-4","article-title":"Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial","author":"Verschoor","year":"2024","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","article-title":"Efficacy of lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells\u2014the DETECT III clinical trial","volume":"70","author":"Fehm","year":"2024","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41523-021-00281-1","article-title":"Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients","volume":"7","author":"Paoletti","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41598-017-01066-y","article-title":"Meta-analysis reveals the prognostic value of circulating tumour cells detected in the peripheral blood in patients with non-metastatic colorectal cancer","volume":"7","author":"Lu","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib131","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers13030485","article-title":"Preoperative CTC-Detection by CellSearch\u00ae Is associated with early distant metastasis and impaired survival in resected pancreatic cancer","volume":"13","author":"Hugenschmidt","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib132","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s11605-013-2258-6","article-title":"Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients","volume":"17","author":"Galizia","year":"2013","journal-title":"J. Gastrointest. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib133","article-title":"Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients","volume":"6","author":"Tsai","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib134","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cncy.22304","article-title":"Postoperative circulating tumor cells: an early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection","volume":"128","author":"Sun","year":"2020","journal-title":"Cancer Cytopathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib135","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","article-title":"Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer","volume":"22","author":"Janni","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib136","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/djy018","article-title":"Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis","volume":"110","author":"Bidard","year":"2018","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib137","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdw535","article-title":"Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab","volume":"28","author":"Pierga","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib138","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41598-022-05502-6","article-title":"Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer","volume":"12","author":"Silvestri","year":"2022","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib139","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib140","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib141","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/djy152","article-title":"Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis","volume":"111","author":"Trapp","year":"2019","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104483_bib142","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers14163949","article-title":"Does the presence of circulating tumor cells in high-risk early breast cancer patients predict the site of first metastasis\u2014results from the adjuvant SUCCESS A trial","volume":"14","author":"Trapp","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib143","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","article-title":"Association of circulating tumor cells with late recurrence of estrogen receptor\u2013positive breast cancer","volume":"4","author":"Sparano","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41523-021-00323-8","article-title":"Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid","volume":"7","author":"Vidula","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","article-title":"Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment","volume":"7","author":"Friedl","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib146","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-14-1705","article-title":"Pathological response and circulating tumor cell count identifies treated her2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data","volume":"21","author":"Pierga","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104483_bib147","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-17-0255","article-title":"Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant \u201cGeparquattro\u201d trial","volume":"23","author":"Riethdorf","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib148","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/annonc\/mdr434","article-title":"Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy","volume":"23","author":"Giordano","year":"2012","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib149","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0163","article-title":"Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib150","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.clbc.2018.10.009","article-title":"Detection of HER2-positive circulating tumor cells using the liquidbiopsy system in breast cancer","volume":"19","author":"Chen","year":"2019","journal-title":"Clin. Breast Cancer"},{"issue":"4_Supplement","key":"10.1016\/j.critrevonc.2024.104483_bib151","doi-asserted-by":"crossref","first-page":"P2-02-03","DOI":"10.1158\/1538-7445.SABCS15-P2-02-03","article-title":"Abstract P2-02-03: HER2 expression on circulating tumor cells before adjuvant chemotherapy and during follow-up in patients with HER2-negative early breast cancer","volume":"76","author":"Markomanolaki","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104483_bib152","doi-asserted-by":"crossref","unstructured":"Jaeger B.A.S., Neugebauer J., Andergassen U., et al. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. Santini D., ed. PLoS One. 2017;12(6):e0173593. doi:10.1371\/journal.pone.0173593.","DOI":"10.1371\/journal.pone.0173593"},{"key":"10.1016\/j.critrevonc.2024.104483_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100132","article-title":"Cellular residual disease (CRD) in early breast cancer \u2013expanding the concept of minimal residual disease monitoring?","volume":"3","author":"Serafini","year":"2024","journal-title":"J. Liq. Biopsy"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib154","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3892\/ijo.2015.2824","article-title":"Importance of circulating tumor cells in newly diagnosed colorectal cancer","volume":"46","author":"VAN DALUM","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib155","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/bjc.2015.88","article-title":"Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study","volume":"112","author":"Bork","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib156","first-page":"239","article-title":"Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer","volume":"35","author":"Katoh","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2024.104483_bib157","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.2147\/CMAR.S300554","article-title":"Detection and clinical value of circulating tumor cells as an assisted prognostic marker in colorectal cancer patients","volume":"Volume 13","author":"Pan","year":"2021","journal-title":"Cancer Manag Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104483_bib158","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.7150\/jca.30512","article-title":"Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib159","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3892\/ijo.2015.2824","article-title":"Importance of circulating tumor cells in newly diagnosed colorectal cancer","volume":"46","author":"Van Dalum","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib160","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/biomedicines9091179","article-title":"Clinical relevance of circulating tumor cells in prostate cancer management","volume":"9","author":"Cie\u015blikowski","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib161","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13014-020-01577-5","article-title":"Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study","volume":"15","author":"Zapatero","year":"2020","journal-title":"Radiat. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib162","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00432-014-1775-3","article-title":"Circulating tumor cell detection in high-risk non-metastatic prostate cancer","volume":"140","author":"Loh","year":"2014","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104483_bib163","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.juro.2008.01.102","article-title":"Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer","volume":"179","author":"Davis","year":"2008","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib164","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers12010160","article-title":"Circulating tumor cells as a marker of disseminated disease in patients with newly diagnosed high-risk prostate cancer","volume":"12","author":"Cie\u015blikowski","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib165","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/JU.0000000000000393","article-title":"Identification and characterization of circulating tumor cells in men who have undergone prostatectomy for clinically localized, high risk prostate cancer","volume":"202","author":"Friedlander","year":"2019","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib166","first-page":"1","article-title":"Circulating tumor cells as a predictor of treatment response in clinically localized prostate cancer","author":"Salami","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib167","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2303.2010.00835.x","article-title":"Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method","volume":"23","author":"Hofman","year":"2012","journal-title":"Cytopathology"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib168","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3967\/9\/1\/016005","article-title":"Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology","volume":"9","author":"Wendel","year":"2012","journal-title":"Phys. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib169","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-10-0445","article-title":"Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker","volume":"17","author":"Hofman","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib170","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/ijc.25819","article-title":"Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay\u2122 and the isolation by size of epithelial tumor cell method","volume":"129","author":"Hofman","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104483_bib171","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.3390\/cancers14246112","article-title":"Circulating tumor cells as a predictive biomarker in resectable lung cancer: a systematic review and meta-analysis","volume":"14","author":"Wankhede","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib172","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.21037\/tlcr-22-827","article-title":"Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I\u2013IIIA NSCLC","volume":"12","author":"Garitaonaindia","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib173","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cllc.2019.04.011","article-title":"Early detection of recurrence in patients with locally advanced non\u2013small-cell lung cancer via circulating tumor cell analysis","volume":"20","author":"Chinniah","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib174","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111597","article-title":"\u201cSentinel\u201d circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. Kalinichenko V V., ed","volume":"9","author":"Ilie","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104483_bib175","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-2600(20)30081-3","article-title":"Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study","volume":"8","author":"Marquette","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2024.104483_bib176","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib177","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MPA.0000000000000324","article-title":"Circulating tumor cells found in patients with localized and advanced pancreatic cancer","volume":"44","author":"Kulemann","year":"2015","journal-title":"Pancreas"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib178","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2016.121","article-title":"Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer","volume":"114","author":"Ankeny","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib179","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s13277-013-1327-5","article-title":"Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis","volume":"35","author":"Han","year":"2014","journal-title":"Tumor Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jamcollsurg.2015.05.014","article-title":"Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings","volume":"221","author":"Cauley","year":"2015","journal-title":"J. Am. Coll. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100416","article-title":"Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer","volume":"7","author":"Beije","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2024.104483_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2016.09.031","article-title":"Detection of circulating tumour cells may add value in endometrial cancer management","volume":"207","author":"Ni","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib183","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41419-022-05350-2","article-title":"Liquid biopsy in gastric cancer: predictive and prognostic biomarkers","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104483_bib184","doi-asserted-by":"crossref","first-page":"12060","DOI":"10.7150\/thno.48918","article-title":"Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104483_bib185","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/cancers15143630","article-title":"Presence of circulating tumor cells predates imaging detection of relapse in patients with stage III melanoma","volume":"15","author":"Lucci","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104483_bib186","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2022.03.013","article-title":"The potential of liquid biopsy in the management of cancer patients","volume":"84","author":"Markou","year":"2022","journal-title":"Semin Cancer Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104483_bib187","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4143\/crt.2022.1026","article-title":"Clinical circulating tumor DNA testing for precision oncology","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib188","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib189","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12916-018-1157-9","article-title":"Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection","volume":"16","author":"Fiala","year":"2018","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006013","article-title":"Cell-free DNA approaches for cancer early detection and interception","volume":"11","author":"Medina","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104483_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1172108","article-title":"Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Genet."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104483_bib192","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/2159-8290.CD-17-0891","article-title":"Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C Phase II colorectal cancer clinical trial","volume":"8","author":"Khan","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib193","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.semradonc.2015.05.001","article-title":"Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA","volume":"25","author":"Chaudhuri","year":"2015","journal-title":"Semin Radiat. Oncol."},{"issue":"504","key":"10.1016\/j.critrevonc.2024.104483_bib194","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib195","article-title":"The emerging role of liquid biopsies in revolutionising cancer diagnosis and therapy","volume":"15","author":"Shegekar","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib196","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41416-023-02445-1","article-title":"Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors","volume":"129","author":"Thompson","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib197","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050940","article-title":"ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer","volume":"16","author":"Desai","year":"2024","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104483_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083815","article-title":"Future perspectives in detecting EGFR and ALK gene alterations in liquid biopsies of patients with NSCLC","volume":"22","author":"Ferreira","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib199","article-title":"The impact of on-target resistance mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 insertion mutation active tyrosine kinase inhibitors","volume":"5","author":"Kobayashi","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104483_bib200","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib201","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-024-03026-7","article-title":"Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation","volume":"43","author":"Ren","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104483_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing","volume":"121","author":"Venetis","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104483_bib203","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib204","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104483_bib205","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","article-title":"Circulating tumour DNA - looking beyond the blood","volume":"19","author":"Tivey","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2024.104483_bib206","first-page":"ii33","article-title":"Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma","volume":"4","author":"Friedman","year":"2022","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.critrevonc.2024.104483_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100140","article-title":"Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases","volume":"4","author":"Desai","year":"2024","journal-title":"J. Liq. Biopsy"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104483_bib208","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","article-title":"Cell-free DNA analysis in current cancer clinical trials: a review","volume":"126","author":"Cisneros-Villanueva","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104483_bib209","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225372","article-title":"Recent progress in enhanced cancer diagnosis, prognosis, and monitoring using a combined analysis of the number of circulating tumor cells (CTCs) and other clinical parameters","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104483_bib210","doi-asserted-by":"crossref","first-page":"10-10","DOI":"10.21037\/tbcr-23-55","article-title":"Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer","volume":"5","author":"Nicol\u00f2","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104483_bib211","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/ijc.32056","article-title":"Single tube liquid biopsy for advanced non-small cell lung cancer","volume":"144","author":"de Wit","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104483_bib212","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1002\/1878-0261.13094","article-title":"Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab","volume":"15","author":"Mondelo-Mac\u00eda","year":"2021","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104483_bib213","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/diagnostics12040870","article-title":"Combinatorial Power of cfDNA, CTCs and EVs in Oncology","volume":"12","author":"Keup","year":"2022","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01909-5","article-title":"The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis","volume":"22","author":"Guo","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-023-02491-9","article-title":"Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer","volume":"130","author":"Eslami-S","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib216","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00544-y","article-title":"Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer","volume":"11","author":"de Miguel-Perez","year":"2023","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02401-0","article-title":"Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal","volume":"18","author":"Yang","year":"2020","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104483_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T20:25:07Z","timestamp":1726172707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":218,"alternative-id":["S1040842824002269"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104483","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104483"}}